Remogliflozin etabonate: Phase I data

An open-label, U.S. Phase I trial showed that there was no significant increase in area under the curve (AUC) or half-life of remogliflozin in 17 subjects with mild or moderate renal impairment following treatment with a single 250 mg dose of the compound compared to 17 matched healthy controls with normal renal function. Additionally, pharmacodynamic measurements of urinary glucose excretion showed no changes in the ability of remogliflozin to inhibit SGLT2 in patients with mild or moderate renal impairment. BHV said the results are "notable because other SGLT2 inhibitors appear to accumulate and lose efficacy" in subjects with renal impairment. The company said the Phase I data indicate that no dose adjustment of remogliflozin would be necessary in patients with mild or moderate renal impairment. ...